Hand-assisted laparoscopy confers equal efficacy in simple and radical nephrectomy.

BACKGROUND AND OBJECTIVES: To evaluate outcomes for simple hand-assisted laparoscopic nephrectomy (HALSN). METHODS: A retrospective chart review was performed at our institution for all patients who had undergone HALSN from January 2002 to January 2009. Thirty-three patients underwent HALSN during this time period and were matched with 33 patients who underwent radical handassisted laparoscopic nephrectomy (HALRN). RESULTS: Operative times were similar between both groups (301 vs 286 min for HALSN vs HALRN; P=.54). There were no intraoperative or postoperative transfusions in either group. There was one conversion to open nephrectomy in the HALSN group in a patient with xanthogranulomatous pyelonephritis and no conversions in the HALRN group. The mean opioid equivalence requirement was not statistically different between both groups (110 vs 120 for HALSN vs HALRN, P=.70). Mean hospital stay was similar for patients undergoing HALSN and HALRN (5.0±3.8 days vs 4.0±1.2 days, P=.63). There was 1 major complication in the HALSN group (pulmonary embolus) and no major complications in the HALRN group. Rates of minor complications were comparable between the 2 groups (18% vs 24% for HALSN vs HALRN). CONCLUSIONS: HALSN may be associated with similar operative times and length of postoperative hospital stay as well as comparable complication rates compared to HALRN.

Complications of hand-assisted laparoscopic renal surgery: single-center ten-year experience.

OBJECTIVES: To review our perioperative complications during the first decade of using hand-assisted laparoscopic nephrectomy using a sleeve (HALN). HALN is a minimally invasive procedure first reported by our group in 1997. METHODS: After institutional review board approval, the charts of the patients who had undergone HALN, hand-assisted laparoscopic partial nephrectomy, or hand-assisted laparoscopic nephroureterectomy from 1997 to 2007, at our institution, were retrospectively reviewed. Standard laparoscopic procedures were not included. The relevant patient characteristics, operative details, American Society of Anesthesiologists score, body mass index, comorbidities, medications, and complications were recorded. RESULTS: A total of 227 consecutive patients had undergone Hand-assisted laparoscopic renal surgery, and all their charts were reviewed. Of these 227, 134 were radical HALN, 37 were nonradical HALN, 42 were hand-assisted laparoscopic partial nephrectomy, and 15 were hand-assisted laparoscopic nephroureterectomy. Complications developed in 59 patients (26%): 8% major and 18% minor. The procedure-specific complication rate was 29% for radical HALN, 27% for nonradical HALN, 33% for hand-assisted laparoscopic nephroureterectomy, and 17% for hand-assisted laparoscopic partial nephrectomy. Complications included blood transfusion in 6%, urinary retention in 4%, ileus in 4%, and wound infection in 4%. From 2003 through 2007 (n = 163), our overall complication rate was 22% (8% major and 13% minor). From 1997 to 2002 (n = 65), the overall complication rate was 38% (P = .02). The American Society of Anesthesiologists score and the use of systemic steroids were associated with the occurrence of perioperative complications. CONCLUSIONS: Our results have shown that hand assistance provides a safe, minimally invasive laparoscopic procedure. Our complications rates were comparable to those with other standard and hand-assist series, although the spectrum of complications varied. Hand-assisted laparoscopic renal surgery could be a method by which to improve patient access to minimally invasive nephron-sparing surgery.

Renal angiomyolipoma with inferior vena caval thrombus in a 32-year-old male.

Renal angiomyolipoma (AML) rarely presents with evidence of extension into the renal vein, inferior vena cava (IVC) or atrium. We report a case of a renal AML with a tumor thrombus to the IVC in a 32-year-old male. The patient subsequently underwent a right radical nephrectomy with IVC tumor thrombectomy. To our knowledge, there are four published cases of renal AML presenting with tumor thrombus in males. This case report describes the management of the youngest male ever to develop a renal AML with IVC tumor thrombus.

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin.

OBJECTIVE: To evaluate the recurrence-free survival (RFS) rate of patients taking cardioprotective aspirin after intravesical bacille Calmette-Guérin (BCG) for high-grade noninvasive urothelial carcinoma of the bladder, as preventing the recurrence of superficial bladder cancer might decrease patient morbidity and mortality from this disease, and nonsteroidal anti-inflammatory agents (NSAIDs) have shown promise in preclinical prevention through inhibition of the prostaglandin pathway and other mechanisms. PATIENTS AND METHODS: In all, 43 patients with carcinoma in situ (CIS) and/or high-grade papillary bladder cancer were treated with intravesical BCG. Patients were stratified according to whether they took cardioprotective aspirin after treatment, and Kaplan-Meier curves of RFS were compared by log-rank analysis. Multivariable analysis was used for potentially confounding factors, including maintenance BCG, the presence of CIS, and smoking status. RESULTS: Of patients taking cardioprotective aspirin, the 5-year RFS rate was 64.3%, compared with 26.9% for patients not taking aspirin, with a significantly higher RFS by univariable log rank analysis (P = 0.03). Even after adjusting for the other factors by multivariable analysis, aspirin seems to affect recurrence (hazard ratio 0.179, P = 0.001). Maintenance BCG (hazard ratio 0.233, P = 0.02) and smoking history (hazard ratio 3.199, P = 0.05) also significantly affected recurrence. CONCLUSION: There was a significantly higher RFS rate in patients taking cardioprotective aspirin after intravesical BCG therapy for bladder cancer. The results of this study support the further investigation of aspirin and other NSAIDs as preventive agents in patients being treated for superficial bladder cancer.

Single center preliminary experience with hand-assisted laparoscopic resection of isolated renal cell carcinoma fossa recurrences.

OBJECTIVES: Solitary metastasis to the renal fossa after radical nephrectomy for renal cell carcinoma is uncommon. We report the first series on hand-assisted laparoscopic excision for renal cell carcinoma fossa recurrences. METHODS: We performed a retrospective review of patients who underwent hand-assisted laparoscopic excision of renal cell carcinoma fossa recurrence. Patients with distant metastasis or local lymph node or adrenal metastasis were excluded from analysis. We collected data on patient and tumor characteristics, nephrectomy and fossa mass excision procedures, and postoperative outcomes. RESULTS: Between 2001 and 2007, 5 patients underwent laparoscopic resection of a renal fossa recurrence. Mean time to recurrence after radical nephrectomy was 23 months (range, 5 to 46 months) and mean size of the renal fossa mass was 6 cm (range, 4.2 to 9.5 cm). The average operative time was 232 minutes (range, 150 to 300 minutes) and average estimated blood loss was 175 mL (range, 25 to 400 mL). One patient required conversion to open surgery. There were no postoperative complications and mean hospital stay was 4 days. With mean follow-up of 43 months, the cancer-specific and disease-free survival rates were 60% and 20%, respectively. Of the 4 patients who underwent complete resection, 2 died from metastatic disease at 13 and 56 months, 1 continues to have progressive metastatic disease at 69 months, and 1 remains free of any clinical evidence of metastatic disease or recurrence at 37 months. One patient who underwent incomplete resection as a result of inferior vena cava invasion continues to have progressive local and distant metastatic disease at 40-month follow-up. CONCLUSIONS: Hand-assisted laparoscopic excision of renal fossa recurrence after radical nephrectomy appears to be safe and effective for carefully selected patients.

Comparison of blade temperature dynamics after activation of Harmonic Ace scalpel and the Ultracision Harmonic Scalpel LCS-K5.

PURPOSE: To compare tip temperatures of the vibrating blades of the newer-generation Harmonic Ace device and the older-generation Ultracision Harmonic Scalpel LCS-K5. MATERIALS AND METHODS: Comparison of two different harmonic scalpel blades was performed by applying them to 3-mm strips of raw chicken breast at room temperature and measuring the temperature of the tip of the vibrating blade at 0.5-second intervals using a thermocouple. Following activation, the tip was allowed to passively cool to 30 degrees C each time before reactivation. Each device was tested at power settings of 3 and 5 after activation for 1 to 5 seconds. All measurements were performed 5 times. RESULTS: Compared to the older-generation Ultracision Harmonic Scalpel LCS-K5, the newer-generation Harmonic Ace was associated with higher tip temperatures at power level 5 at all times of activation (1-5 seconds), and at power level 3 at longer times of activation (3-5 seconds). The Harmonic Ace also takes longer to reach peak temperatures and can maintain blade hyperthermia for a longer period after activation for more than 3 seconds at power levels 3 and 5. CONCLUSION: The newer-generation Harmonic Ace may be potentially more effective in tissue dissection, but is associated with greater increases in peak temperatures and longer blade hyperthermia periods compared to the older-generation Ultracision Harmonic Scalpel LCS-K5. The difference is greater after longer periods of activation, and this may have more potential for collateral damage, particularly to nerves and bowel.

Oncological outcomes of hand-assisted laparoscopic radical nephrectomy for clinically localized renal cell carcinoma: a single-institution study with >or=3 years of follow-up.

OBJECTIVE: To evaluate the intermediate-term outcomes of hand-assisted laparoscopic radical nephrectomy (HALRN) for clinically organ-confined renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively reviewed patients who had HALRN for clinically organ-confined RCC at the University of Wisconsin from 1996 to 2003. All patients with pathologically confirmed RCC and with >or=3 years of follow-up were included in a retrospective chart review of variables before, during and after HALRN, as well as the clinical outcomes. RESULTS: In all, 75 patients had HALRN in the study period; their mean age was 59 years, body mass index 29 kg/m(2), operative duration 227 min, estimated blood loss 130 mL, and none required conversion to open nephrectomy. The median time to first oral intake was 2.5 days and the median hospital stay 4 days. On pathological examination the mean tumour size was 5.8 cm; 70% were pT1, 26% pT2 and 4% pT3; 82% were clear cell, 9% papillary, 8% chromophobe and 1% collecting duct carcinoma. Of the 65 patients who had a follow-up of >or=36 months (mean 46, range 36-117), the 3- and 5-year disease-free survival rate was 93.4% and 90.2%, respectively; the 3- and 5-year cancer-specific survival rate was 96.5% and 94.4%, respectively. CONCLUSION: Our study suggests that HALRN is a safe and minimally invasive treatment for managing clinically organ-confined RCC, with good intermediate-term oncological outcomes.

Bacterial prostatitis.

Prostatitis is perhaps the most common urologic complaint in men younger than 50 years of age and affects 11% to 16% of American men over the course of their lifetimes. Prostatitis syndromes have a significant psychologic impact upon patients who suffer from them and place an enormous financial strain upon the health care system. Despite many advances in our understanding of the pathogenesis and treatment of prostatitis, current management strategies are unable to provide a significant portion of relief from symptoms. In this article, we focus on bacterial prostatitis (types I and II), with an emphasis on new understandings of pathogenesis, diagnosis, and treatment strategies for these often challenging patients.

Doxazosin relaxes ureteral smooth muscle and inhibits epinephrine-induced ureteral contractility in vitro.

OBJECTIVES: Although recent evidence has supported increased ureteral stone passage with selective alpha(1)-adrenergic receptor antagonists, no mechanistic study evaluating ureteral relaxation by alpha(1) antagonism has been reported to date. We evaluated whether the alpha-blocker doxazosin reduces spontaneous, and inhibits alpha(1)-agonist-induced ureteral contractility. Additionally, alpha-receptor subtypes in normal and obstructed human ureter were analyzed. METHODS: We exposed porcine ureters in organ tissue baths with 0.1, 1.0, or 10 microM doxazosin and recorded the tension for 90 minutes. After the initial treatment, a concentration-response curve of epinephrine or phenylephrine (1 nM to 10 microM) was generated. The experiment was repeated with the proximal, mid-, and distal ureter. The relative expression of the alpha 1A, 1B, and 1D receptor subtypes in normal and obstructed human ureters was analyzed using immunoblotting. RESULTS: Doxazosin reduced the spontaneous ureteral contractility rates in a concentration-dependent fashion by 23% to 34%. A more pronounced relaxation effect by doxazosin was evident when epinephrine was introduced to the tissues. In 1 and 10-microM doxazosin-pretreated tissues, epinephrine caused 89% and 100% relaxation, respectively. Phenylephrine-induced contractions were antagonized by doxazosin but not reversed to any relaxant function. No differential expression of alpha(1)-receptor subtypes was identified in the obstructed versus normal ureters. CONCLUSIONS: The results of our study have shown that alpha(1)-receptor blockade decreases ureteral contractility and inverses the effect of epinephrine, providing even greater relaxation. We hypothesize that alpha receptor blockade might relax the ureter and induce stone passage by way of epinephrine activation of beta receptors. Additional studies should be performed to validate this hypothesis and to compare various alpha(1)-receptor subtype antagonists.

Cryoablation of small renal masses: assessment of the outcome at one institution.

OBJECTIVE: To report our 5-year experience with laparoscopic and percutaneous cryoablation (LCA and PCA) for managing small renal masses. PATIENTS AND METHODS: We retrospectively analysed patients undergoing LCA and PCA between October 2000 and March 2006 at our institution. After approval from the Institutional Review Board, charts were reviewed retrospectively for variables during and after CA, and for clinical outcomes, the latter including the efficacy of the procedure in achieving overall, cancer-specific and recurrence-free survival. RESULTS: In all, 78 patients had CA of 88 small renal masses, by LCA in 58 and PCA in 20. The median American Society of Anesthesiology score was 3 and the mean body mass index was 30 kg/m(2). All procedures were done under general anaesthesia, with a mean anaesthesia time of 220 min. The mean tumour size was 2.6 cm and the mean hospital stay was 2.1 days. At a mean follow-up of 19 months, the overall, cancer-specific and recurrence-free survival rates were 88.5%, 100% and 98.7%, respectively. Four patients required a repeat treatment due to persistent disease and one had progression to locally advanced disease. Five patients had complications during CA and seven had complications afterward. CONCLUSION: This study suggests that CA is a safe, minimally invasive treatment option for patients with small renal masses, at the intermediate-term follow-up.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

BACKGROUND: Common risk factors for osteoporosis in older men include smoking, heavy use of alcohol, propensity to falls, and use of bone-toxic medications such as prednisone. There is also increasing appreciation of the skeletal risk faced by men receiving androgen deprivation therapy (ADT) for prostate cancer. Measures to prevent bone loss in such patients are available. OBJECTIVE: To test the following hypotheses in a population of veterans receiving ADT for prostate cancer: (1) fracture risk factors in addition to androgen deprivation would be found in most patients, (2) bone mass measurements would be assessed in a minority of patients, and (3) a minority of the subjects would receive bisphosphonate therapy or have contraindications for such treatment. METHODS: We conducted a retrospective chart review of male veterans receiving ADT from 1993 through 2001, at the Veterans Affairs Medical Center, Madison, WI. RESULTS: One hundred and seventy-four subjects met study criteria, with a mean age of 76 years and median duration of 21 months of ADT. Eighty-one percent had risk factors in addition to ADT. Only 13% underwent bone density measurement by dual energy X-ray absorptiometry (DXA) and, of those measured, more than half had osteoporosis. Only 19% of the men received both calcium and vitamin D supplements. Antiresorptive therapy was provided to 11% of men, although more than two-thirds had no contraindications to therapy. A total of 24 men sustained a fracture after starting ADT. For men who did undergo bone density measurement, 77% received antiresorptive therapy. Of those who exhibited osteoporosis by DXA scan, 85% received antiresorptive therapy. CONCLUSIONS: Male veterans receiving ADT for prostate cancer received inadequate evaluation and treatment for osteoporosis. Based on our data, a simple and practical strategy to prompt further evaluation and improved care may be to undertake bone density measurements in men prior to or soon after commencing ADT.

Maintaining urine production and early allograft function during laparoscopic donor nephrectomy.

OBJECTIVES: Intraoperative oliguria and its impact on early postoperative allograft function have been expressed as potential concerns of laparoscopic kidney donation. We evaluated our ability to maintain adequate diuresis during laparoscopic donor nephrectomy and its potential impact on early graft function compared with open donation. METHODS: We performed a retrospective review of 98 laparoscopic and 80 open donor nephrectomies from 1999 to 2002. All laparoscopic donors received infusions of mannitol (grams of mannitol equaled patient weight in kilograms) and dopamine (2 to 3.0 microg/kg/min) throughout the pneumoperitoneum. All open donors received a single dose of mannitol (12.5 g). Multiple donor variables were compared, including operative time, estimated blood loss, intraoperative fluid administration (in milliliters per kilogram per hour), intraoperative urine production (milliliters per kilogram per hour), and change in creatinine at discharge. The postoperative recipient data were compared, including initial 24-hour urine output, 1-week creatinine level, 1-month creatinine level, and need for postoperative hemodialysis. RESULTS: No significant differences were noted in the donor groups with respect to age, weight, intraoperative fluid administration, or change in creatinine at discharge. The mean operative urine production was greater in the laparoscopic group at 5.22 mL/kg/hr than in the open group at 2.43 mL/kg/hr (P = 0.0001). The mean estimated blood loss was significantly lower (P = 0.0001) for the laparoscopic donors (106.7 mL) than for the open donors (184.7 mL). No significant differences were seen among the recipient groups. CONCLUSIONS: The use of mannitol and dopamine infusions during laparoscopic donor nephrectomy provided superior intraoperative urine production in the donor and equivalent early graft function in the recipient compared with the open approach.

Examination of laparoscopic retrieval bag washings for malignant cells after hand-assisted laparoscopic radical nephrectomy and intact specimen removal.

OBJECTIVES: Port site metastases after hand-assisted laparoscopic radical nephrectomy have been described in the literature. There is no uniform agreement among urologists regarding the use of a retrieval bag before intact specimen removal. The aim of this study was to determine whether LapSac renal extraction bag washings contain malignant cells. METHODS: We prospectively obtained washings from the LapSac retrieval bag after hand-assisted laparoscopic radical nephrectomy and intact specimen removal for renal cell carcinoma. In 30 consecutive cases, after removal of the kidney specimen from the LapSac, the LapSac was irrigated with 50 mL sterile Hank's balanced salt solution. These washings were sent for cytologic examination. Cytologic evaluation was performed with a Thin Prep and the Papanicolaou method. RESULTS: We performed 30 hand-assisted laparoscopic radical nephrectomies for suspected renal cell carcinoma with the above protocol. One specimen was benign and one showed transitional cell carcinoma; these were excluded from the study. Six specimens were stage T1a, 17 were T1b, 1 was T2, 2 were T3a, and 2 were T3b. Histopathology revealed 27 specimens with clear cell renal cell carcinomas with Fuhrman grades from 1 to 4; 1 specimen showed chromophobe renal cell carcinoma. Margins were negative in all cases, and there were no gross or microscopic tumor violations. The cytologic results from 27 cases were negative and in 1 case with T3b renal cell carcinoma the LapSac washings were positive for malignant cells. CONCLUSIONS: The preliminary findings from our study show that low-stage, low-grade tumors removed laparoscopically with minimal manipulation do not exfoliate cells into their LapSac retrieval bags.

Magnetic resonance imaging findings after laparoscopic renal cryoablation.

OBJECTIVES: To assess the magnetic resonance imaging (MRI) appearance of renal masses after laparoscopic cryoablation. METHODS: Between October 2000 and June 2004, 33 patients underwent laparoscopic cryoablation of 34 renal masses, 24 of whom (25 renal masses, size range 1.5 to 3.7 cm, mean 2.4) were followed up with MRI postoperatively. Postoperative MRI was done at 1, 3, and 6 months after ablation and every 6 months thereafter using a 1.5-T MRI scanner. T1-weighted dual-phase, coronal T1-weighted fat-saturated, and T2-weighted coronal and axial MRI was done before contrast administration. Postenhancement images were obtained in the coronal and axial planes during the arterial, venous, and delayed phases. RESULTS: Patient follow-up data were available for at least 6 months and up to 48 months for 18 patients. On the first follow-up MRI study, six lesions had increased in size, five had decreased in size, and seven showed no change. Of the 18 patients, 7 had peripheral rim enhancement within 3 months of follow-up. Four resolved. One patient developed rim enhancement at 7 months postoperatively. Subsequent images revealed lesion enlargement with heterogeneous enhancement. Biopsy was positive for renal cell carcinoma. One patient developed nodular enhancement at 10 months with a decrease in lesion size. Watchful waiting was chosen because the patient had significant medical comorbidities. CONCLUSIONS: Peripheral rim enhancement is a common finding on MRI immediately after laparoscopic renal cryoablation. Rim enhancement with an increase in lesion size or nodular enhancement is of more concern than rim enhancement alone. More data are necessary to understand the progression of renal lesions after cryoablation.

Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study.

PURPOSE: We evaluated the efficacy and tolerability of pentosan polysulfate sodium (PPS) for the treatment of men with chronic pelvic pain syndrome (CPPS), National Institutes of Health (NIH) category III. MATERIALS AND METHODS: In a 16-week double-blind study 100 men with a clinical diagnosis of CPPS were randomized to receive 300 mg PPS or placebo 3 times daily. Clinical Global Improvement (CGI) was the primary outcome measure. Additional outcome measures were the NIH-Chronic Prostatitis Symptom Index (CPSI), Subjective Global Assessment and Symptom Severity Index assessment tools. RESULTS: Significantly more patients receiving PPS experienced moderate to marked improvement based on CGI assessment (18 or 37% vs 8 or 18%, p = 0.04). However, mean CGI scores were not significantly different between the PPS group (1.0) and placebo groups (1.0 vs 0.6, p = 0.107). All NIH-CPSI domains suggested a positive effect for PPS and for total NIH-CPSI the difference approached statistical significance (-5.9 or 22% vs -3.2 or 12%, p = 0.068). The PPS group showed significantly greater improvement in NIH-CPSI quality of life domain scores than the placebo group (-2.0 or 22% vs -1.0 or 12%, p = 0.031). Of patients receiving PPS 67% and 80% of those receiving placebo completed the 16-week study. Diarrhea, nausea and headache were the most common adverse events. CONCLUSIONS: Pentosan polysulfate (900 mg daily) was more likely than placebo to provide relief for CPPS symptoms.

Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review.

PURPOSE: Ablative treatments (cryoablation or radio frequency ablation) for renal cell carcinoma aim to decrease morbidity by treating renal tumors in situ, eliminating the need for extirpation. These technologies have potential for complications previously unassociated with renal tumor treatment. We identified complications associated with percutaneous and laparoscopic ablative treatment of renal tumors. MATERIALS AND METHODS: Groups at medical centers with reported experience with ablation of renal tumors were invited to participate in this study. Each group submitted retrospective data regarding overall ablative treatment experience and associated complications. For each incident the nature of the complication, its associated morbidity, the necessity and nature of any subsequent interventions, and the final patient outcome were evaluated. Complications were divided into minor and major categories. Data were collected from groups at 4 institutions with a combined experience of 271 cases. Of these cases 139 were cryoablation and 133 were radio frequency ablation. There were 181 procedures performed percutaneously and 90 performed laparoscopically. RESULTS: A total of 30 complications occurred (11.1%) with 5 major (1.8%) and 25 minor (9.2%) complications, and 1 death (0.4%). Overall 26 of the 30 complications (86.7%) were directly attributable to the ablation procedure. The most common complication was pain or paraesthesia at the probe insertion site. CONCLUSIONS: Ablation technologies appear to have a low complication profile when used to treat small renal tumors. The majority of complications are minor and require observation only. Further study and followup are necessary to determine long-term oncological efficacy.

Laparoscopic cryoablation under sonographic guidance for the treatment of small renal tumors.

PURPOSE: To evaluate the efficacy of ultrasound-guided laparoscopic cryoablation of small renal tumors. PATIENTS AND METHODS: Eleven men and five women with solid renal tumors (mean size 2.6 cm) were treated using laparoscopically monitored cryoablation between October 2000 and October 2002. Nine tumors were left sided and seven right. Ten patients were treated retroperitoneoscopically and six transperitoneally. A double-freeze/active-thaw technique was utilized with two 10-minute freeze cycles. RESULTS: The mean operating time was 188 minutes. There was one open conversion for failure to progress. The mean blood loss was 40 mL. Tumor biopsy demonstrated five renal-cell carcinomas, two oncocytomas, and lesions that either were benign or were not biopsied. The mean hospital stay was 1.9 days with a median stay of 1 day. With a mean follow-up of 9.6 months, all tumors remain nonenhancing and are stable or smaller than the original lesion. Two patients have died of unrelated causes and without evidence of disease. CONCLUSIONS: This series of patients adds to the growing body of literature suggesting that cryoablation is a well-tolerated method for treating small renal tumors. Longer follow-up is required to fully define its place in the therapeutic armamentarium.

Hand-assisted laparoscopic renal surgery in the morbidly and profoundly obese.

BACKGROUND AND PURPOSE: Obesity has been regarded as a relative contraindication to standard laparoscopic procedures. We evaluated the impact of morbid (body mass index [BMI] >30 kg/m2) and profound (BMI > 40 kg/m2) obesity on the results of hand-assisted laparoscopic renal surgery (HALRS). PATIENTS AND METHODS: From September 1996 until October 2002, a total of 30 patients among 105 on whom HALRS was performed at our institution were morbidly obese, with a mean BMI of 35.8 kg/m2 (range 30.3-52.3 kg/m2). Eight patients were noted to have profound obesity, with a mean BMI of 44 kg/m2 (range 40.1-52.3 kg/m2). The HALRS procedures included radical nephrectomy in 23 patients, simple nephrectomy in 4, nephroureterectomy in 2, and partial nephrectomy in 1. At least one additional significant comorbidity was noted in 70% of these patients. We retrospectively evaluated the intraoperative and postoperative outcomes in this group of obese patients. RESULTS: All procedures were performed successfully without the need for open conversion. The mean operative time was 262 minutes (range 125-361 minutes), and the mean estimated blood loss was 217 mL (range 50-600 mL). No transfusions or intraoperative complications occurred. The mean hospital stay was 4.1 days (range 2-13 days). There were 7 minor postoperative complications including ileus (N = 5), wound cellulitis (1), and urinary retention (1). No complications occurred in the profoundly obese patient subgroup. CONCLUSIONS: Hand-assisted laparoscopic renal surgery is safe and effective in the morbidly and profoundly obese patient.

Symptomatic port-site hernia associated with a non-bladed trocar after laparoscopic live-donor nephrectomy.

We describe what appears to be the first case of a port-site hernia at the site of insertion of a 10-mm non-bladed trocar, which was discovered 4 days after laparoscopic live-donor nephrectomy. We now close all 10-mm port sites in adults and all 5-mm port sites in children; this can be done easily using the Carter-Thomason device.